We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Statin Therapy in Older Adults with Chronic Kidney Disease: Primary Prevention of Cardiovascular Disease and Safety Profile in Hypercholesterolemic Patients

MedXY Editorial Team•Oct 20, 2025•Cardiology
cardiovascular diseasechronic kidney diseaseelderlystatins

Highlight

This large territory-wide cohort study using target trial emulation provides strong evidence that statin therapy in hypercholesterolemic older adults with chronic kidney disease (CKD) aged 75 and above is associated with significant reduction in overall cardiovascular disease incidence and all-cause mortality. The study also confirms the safety of statin use in this population, showing no significant increase in myopathies or liver dysfunction. These benefits persist even in very old adults aged 85 years and older.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Impact of Age at Type 1 Diabetes Onset on Mortality and Organ Complications: Insights from a Nationwide Swedish CohortYounger age at type 1 diabetes diagnosis significantly increases risks of mortality, cardiovascular, and kidney complications; each additional year delay in onset reduces these risks. This review synthesizes nationwide cohort findings and cSep 23, 2026Longitudinal Glycemic Trajectories in Adults with Type 1 Diabetes: Insights from a Three-Year Multicenter CGM StudyThis study investigates three-year continuous glucose monitoring trajectories across clinical subgroups of adults with type 1 diabetes to identify factors influencing glycemic control and variability, highlighting the need for individualizeSep 21, 2026Efficacy and Safety of Semaglutide According to Frailty Status: Insights from the SELECT Randomized Clinical Trial Post Hoc AnalysisSemaglutide demonstrates consistent cardiovascular benefits and safety across frailty levels in overweight adults with cardiovascular disease, enhancing quality of life and frailty status without increased adverse events.Sep 21, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Efficacy and Safety of Low-Dose Rivaroxaban in Advanced Chronic Kidney Disease with High Cardiovascular Risk: A Comprehensive Review
Low-dose rivaroxaban failed to reduce cardiovascular events but increased major bleeding in advanced CKD patients at high cardiovascular risk, underscoring the need for cautious anticoagulant use.
Sep 21, 2026
A Synopsis of the 2025 VA/DoD Lipid Management Guideline: What Clinicians Need to KnowConcise review of the 2025 VA/DoD lipid guideline: new risk tool (PREVENT), CAC and one-time Lp(a) for risk refinement, statins for selected primary prevention groups (including people with HIV), and intensified combination therapy for verySep 19, 2026
KDIGO 2026 on Anemia in CKD: Key Recommendations and Practical Guidance for CliniciansKDIGO 2026 updates anemia care in CKD: evidence-based thresholds for iron therapy, preference for IV iron on hemodialysis, ESA-first approach over HIF-PHIs, individualized Hb initiation, and an ESA maintenance upper Hb target <11.5 g/dL.Sep 18, 2026